BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36555262)

  • 21. Applications of self-replicating RNA.
    Lundstrom K
    Int Rev Cell Mol Biol; 2022; 372():97-157. PubMed ID: 36064268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Self-Replicating RNA Viruses for RNA Therapeutics.
    Lundstrom K
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30551668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-replicating vehicles based on negative strand RNA viruses.
    Lundstrom K
    Cancer Gene Ther; 2023 Jun; 30(6):771-784. PubMed ID: 35169298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measles virus for cancer therapy.
    Russell SJ; Peng KW
    Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Jung MY; Offord CP; Ennis MK; Kemler I; Neuhauser C; Dingli D
    Cancer Res; 2018 Oct; 78(20):5992-6000. PubMed ID: 30115692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heat shock protein inhibitors increase the efficacy of measles virotherapy.
    Liu C; Erlichman C; McDonald CJ; Ingle JN; Zollman P; Iankov I; Russell SJ; Galanis E
    Gene Ther; 2008 Jul; 15(14):1024-34. PubMed ID: 18356818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic measles virus retargeting by ligand display.
    Msaouel P; Iankov ID; Allen C; Russell SJ; Galanis E
    Methods Mol Biol; 2012; 797():141-62. PubMed ID: 21948475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.
    Msaouel P; Opyrchal M; Dispenzieri A; Peng KW; Federspiel MJ; Russell SJ; Galanis E
    Curr Cancer Drug Targets; 2018; 18(2):177-187. PubMed ID: 28228086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemovirotherapeutic Treatment Using Camptothecin Enhances Oncolytic Measles Virus-Mediated Killing of Breast Cancer Cells.
    Tai CJ; Liu CH; Pan YC; Wong SH; Tai CJ; Richardson CD; Lin LT
    Sci Rep; 2019 May; 9(1):6767. PubMed ID: 31043633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measles virus as an oncolytic vector platform.
    Blechacz B; Russell SJ
    Curr Gene Ther; 2008 Jun; 8(3):162-75. PubMed ID: 18537591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma.
    Lal S; Raffel C
    Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
    Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ
    Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Photocontrollable mononegaviruses.
    Tahara M; Takishima Y; Miyamoto S; Nakatsu Y; Someya K; Sato M; Tani K; Takeda M
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11587-11589. PubMed ID: 31138700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.
    Iankov ID; Allen C; Federspiel MJ; Myers RM; Peng KW; Ingle JN; Russell SJ; Galanis E
    Mol Ther; 2012 Jun; 20(6):1139-47. PubMed ID: 22334023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.
    Deyle DR; Escobar DZ; Peng KW; Babovic-Vuksanovic D
    Gene; 2015 Jul; 565(1):140-5. PubMed ID: 25843626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
    Nettelbeck DM; Leber MF; Altomonte J; Angelova A; Beil J; Berchtold S; Delic M; Eberle J; Ehrhardt A; Engeland CE; Fechner H; Geletneky K; Goepfert K; Holm PS; Kochanek S; Kreppel F; Krutzke L; Kühnel F; Lang KS; Marchini A; Moehler M; Mühlebach MD; Naumann U; Nawroth R; Nüesch J; Rommelaere J; Lauer UM; Ungerechts G
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opportunities to debottleneck the downstream processing of the oncolytic measles virus.
    Loewe D; Dieken H; Grein TA; Weidner T; Salzig D; Czermak P
    Crit Rev Biotechnol; 2020 Mar; 40(2):247-264. PubMed ID: 31918573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Self-Amplifying RNA Viruses as RNA Vaccines.
    Lundstrom K
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.